stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) Return on assets
Iovance Biotherapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −23.3%, up 19.6 percentage points from fiscal 2025 (−42.9%). Over the past ten years it has ranged from −73.8% (fiscal 2016) to −36.4% (fiscal 2015); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −42.9% | 1.14 |
| FY2024 | −44.0% | 17.47 |
| FY2023 | −61.5% | (6.56) |
| FY2022 | −54.9% | (10.65) |
| FY2021 | −44.3% | 2.36 |
| FY2020 | −46.6% | 1.22 |
| FY2019 | −47.9% | (9.01) |
| FY2018 | −38.9% | 17.41 |
| FY2017 | −56.3% | 17.49 |
| FY2016 | −73.8% | (37.39) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 23.2% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ABCL AbCellera Biologics Inc. compare | −12.2% |
| TNGX Tango Therapeutics, Inc. compare | −18.9% |
| IOVA Iovance Biotherapeutics, Inc. | −23.3% |
| RLAY Relay Therapeutics, Inc. compare | −33.7% |
| IRON Disc Medicine, Inc. compare | −35.1% |
| EWTX Edgewise Therapeutics, Inc. compare | −36.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −41.5% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on IOVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement